# The pill, dubbed MK 8527, is currently undergoing a pair of late-stage clinical trials.

*biotech · news · 2026-04-07 · STAT*

## Key points

- Merck's experimental HIV prevention pill could be produced for under $5 per patient annually.
- The pill, MK 8527, is in late-stage clinical trials with results expected in late 2027.
- Mid-stage results showed MK 8527 can provide PrEP protection within 24 hours of ingestion.
- MK 8527 operates via a novel mechanism distinct from existing HIV prevention drugs.

**Companies:** Merck

[Read the full story on STAT](https://www.statnews.com/pharmalot/2026/04/07/merck-experimental-hiv-prevention-pill-made-for-five-dollars-year/)

---

Canonical: https://newsio.io/n/16acb451-6bf9-4b50-9545-37e630eb2cb2/the-pill-dubbed-mk-8527-is-currently-undergoing-a-pair-of-late-stage-clinical-tr
Summarized by Newsio from STAT. https://newsio.io/how-it-works